ATE422367T1 - Zusammensetzungen aus demethylierenden mitteln als verstärker der immuntherapie zur behanldung von chronischen infektionen und neoplastischen erkrankungen und behandlungsverfahren dafür - Google Patents

Zusammensetzungen aus demethylierenden mitteln als verstärker der immuntherapie zur behanldung von chronischen infektionen und neoplastischen erkrankungen und behandlungsverfahren dafür

Info

Publication number
ATE422367T1
ATE422367T1 AT05750379T AT05750379T ATE422367T1 AT E422367 T1 ATE422367 T1 AT E422367T1 AT 05750379 T AT05750379 T AT 05750379T AT 05750379 T AT05750379 T AT 05750379T AT E422367 T1 ATE422367 T1 AT E422367T1
Authority
AT
Austria
Prior art keywords
treatment
compositions
immunotherapy
enhancers
neoplastic diseases
Prior art date
Application number
AT05750379T
Other languages
English (en)
Inventor
Jean-Marie Andrieu
Louis Wei-Lu
Original Assignee
Biovaxim Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovaxim Ltd filed Critical Biovaxim Ltd
Application granted granted Critical
Publication of ATE422367T1 publication Critical patent/ATE422367T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05750379T 2004-05-26 2005-05-26 Zusammensetzungen aus demethylierenden mitteln als verstärker der immuntherapie zur behanldung von chronischen infektionen und neoplastischen erkrankungen und behandlungsverfahren dafür ATE422367T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57463804P 2004-05-26 2004-05-26
US58245504P 2004-06-24 2004-06-24
US11/138,171 US20050266012A1 (en) 2004-05-26 2005-05-26 Compositions comprising demethylating agents as enhancers of immunotherapy for the treatment of chronic infections and neoplastic diseases and methods for treating the same

Publications (1)

Publication Number Publication Date
ATE422367T1 true ATE422367T1 (de) 2009-02-15

Family

ID=35425543

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05750379T ATE422367T1 (de) 2004-05-26 2005-05-26 Zusammensetzungen aus demethylierenden mitteln als verstärker der immuntherapie zur behanldung von chronischen infektionen und neoplastischen erkrankungen und behandlungsverfahren dafür

Country Status (6)

Country Link
US (1) US20050266012A1 (de)
EP (1) EP1748792B1 (de)
AT (1) ATE422367T1 (de)
DE (1) DE602005012686D1 (de)
ES (1) ES2322172T3 (de)
WO (1) WO2005115450A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
PT2750768T (pt) 2011-08-30 2018-12-19 Astex Pharmaceuticals Inc Formulações de derivados de decitabina
SG10201707135RA (en) * 2013-03-01 2017-10-30 Astex Pharmaceuticals Inc Drug combinations
EP2952182B1 (de) * 2014-06-04 2022-11-23 Universität Heidelberg Verbindungen und Verfahren zur Erhöhung der Immunreaktion gegen Papillomavirus
BR112018000054A2 (pt) 2015-07-02 2018-09-04 Otsuka Pharmaceutical Co., Ltd. composições farmacêuticas liofilizadas
WO2019025863A2 (en) 2017-08-03 2019-02-07 Otsuka Pharmaceutical Co., Ltd. MEDICAMENT COMPOUND AND METHODS OF PURIFICATION
US11419928B2 (en) 2017-10-25 2022-08-23 The Johns Hopkins University Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028940A1 (en) * 1994-04-22 1995-11-02 Department Of The Army Methods for inhibiting human immunodeficiency virus
US20030104576A1 (en) * 1994-10-07 2003-06-05 Jonathan W. Nyce Dna construct, composition, formulations & methods for making the construct & for modulating expression
US20050059682A1 (en) * 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer

Also Published As

Publication number Publication date
WO2005115450A1 (en) 2005-12-08
DE602005012686D1 (de) 2009-03-26
EP1748792A1 (de) 2007-02-07
ES2322172T3 (es) 2009-06-17
US20050266012A1 (en) 2005-12-01
EP1748792B1 (de) 2009-02-11

Similar Documents

Publication Publication Date Title
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
ATE422367T1 (de) Zusammensetzungen aus demethylierenden mitteln als verstärker der immuntherapie zur behanldung von chronischen infektionen und neoplastischen erkrankungen und behandlungsverfahren dafür
ATE426412T1 (de) Adjuvante influenza-vakzine
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
CY1113074T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
NO345046B1 (no) Oral doseringsform
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
ATE419008T1 (de) Adjuvante zusammensetzung und anwendungsverfahren dafür
MX2009005414A (es) Formulaciones liquidas de anticuerpo antirrabico.
MA32388B1 (fr) Immunomodulation par des inhibiteurs d'iap
ATE469657T1 (de) Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
AR059851A1 (es) Anticuerpos de la egfl7 y metodos de uso
DK1740206T3 (da) PHEP, en aminosyrepermease af Staphylococcus Aureus
CY1115900T1 (el) Αντισωματα αντι-ephb4 και μεθοδοι χρησης αυτων
DOP2004000837A (es) Inhibidores de p38 y metodos de uso de ellos (p38 inhibitors and methods of use thereof)
TH128473A (th) แอนติ-il-13 แอนติบอดี ที่ได้รับการจัดการ องค์ประกอบ วิธีและการใช้
UA110458C2 (ru) Інгібітори ns5a вгс

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties